GSK Logo


This site is intended for members of the healthcare profession in Ireland only. Otherwise see Public Site


0.5mg dutasteride / 0.4mg tamsulosin hydrochloride

Product overview >

Information overview of Combodart™, including what Combodart™ is and the administration of Combodart™.


Prescribing Combodart™ >

Information on prescribing Combodart™, including Combodart™’s indications, efficacy and safety information.


Clinical evidence >

Information on the clinical evidence of Combodart™, including CombAT data.


Mode of Action >

An infographic video showing what Combodart™ is, how Combodart™ works and how Combodart™ targets the
underlying cause of BPH.

For further information about GSK’s urology portfolio for the treatment of benign prostatic hyperplasia (BPH), please visit our Urology section.

Combodart™ is a registered trademark of the GlaxoSmithKline Group of Companies
Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

KC: Updated October 2014: IE/DUTT/0033/14b